Chemistry:ErSO
From HandWiki
ErSO is an experimental anticancer drug which induces the unfolded protein response. In tests on mice it was effective at eliminating xenografts of human breast cancer cell lines. While it is at an early developmental stage and this particular molecule may not be developed for medical use, it represents an important proof of concept for inducers of unfolded protein response as a novel class of anti-cancer drugs.[1][2][3][4][5]
References
- ↑ "A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice". Science Translational Medicine 13 (603). July 2021. doi:10.1126/scitranslmed.abf1383. PMID 34290053.
- ↑ "Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer". Journal of Medicinal Chemistry 65 (5): 3894–3912. March 2022. doi:10.1021/acs.jmedchem.1c01730. PMID 35080871.
- ↑ "Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity". RSC Medicinal Chemistry 13 (6): 711–725. June 2022. doi:10.1039/d2md00110a. PMID 35814932.
- ↑ "Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy-Induced Necrosis". Cancer Research 83 (18): 3115–3130. September 2023. doi:10.1158/0008-5472.CAN-23-0157. PMID 37522838.
- ↑ "Abstract 2210 To Die or Not to Die: Controlling Death in Breast and Ovarian Cancer Cells with a Novel Pathway Regulating Anticancer Drug.". Journal of Biological Chemistry 300 (3). March 2024. doi:10.1016/j.jbc.2024.106122.
 |  |
